- Director, Clinical Trials Unit, Neurological Institute, University Hospitals
- Program Director, Vascular Neurology, UH Cleveland Medical Center
- Associate Professor, CWRU School of Medicine
Dr. Sundararajan is a Vascular Neurologist at University Hospitals of Cleveland. As part of the Comprehensive Stroke Center at University Hospitals, she focuses on providing and advancing excellence in care to stroke patients by training the next generation of neurologists and developing new treatments via clinical research. She frequently attends the dedicated Stroke Service at Cleveland Medical Center and mentors residents and fellows both in the inpatient and outpatient settings. She is the Program Director for the Vascular Neurology Fellowship. She is also the Director of the Clinical Trials Unit and co-Principal Investigator for the Case Western Reserve University Regional Coordinating Center for StrokeNet (an NIH funded network of 25 Regional Coordinating Centers across the country for conducting clinical trials in Stroke Research). Dr. Sundararajan serves on the Editorial Board of Stroke and is the Editor for the Illustrated Teaching Cases series.
- Acute Intervention
- Cerebrovascular Disease
- Stroke - Acute Treatment
- Stroke Recovery
- Transient Ischemic Attack (TIA)
Research & Publications
Cerebrovascular Disorders, Stroke Acute Intervention, Stroke Therapy, Stroke Recovery
Certifications & Memberships
- Vascular Neurology - American Board of Psychiatry and Neurology
Fellowship | Cerebrovascular Disease
Cerebrovascular Disease - University Hospitals Of Cleveland (1999 - 2001)
Residency | Neurology
Neurology - University Of Texas Medical School At Houston - Mcgovern Med School (1997 - 1999)
Residency | Neurology
Neurology - Washington University School Of Medicine In St Louis (1996 - 1997)
Internship | Internal Medicine
Internal Medicine - Metrohealth Medical Center (1995 - 1996)
Case Western Reserve University School Of Medicine (1995)
Case Western Reserve University (1993)
University Of Michigan (1987)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Sophia Sundararajan disclosed the following Outside Relationships with Industry:
- - Advanced Cardiovascular Associates - Ownership